Insights On Downstream Manufacturing

  1. Reframing Residual DNA Testing: What It Is--And What It Isn't 2/11/2026

    Residual host-cell DNA quantitation requires sensitive, well-validated analytical workflows to ensure accurate impurity control, process understanding, and regulatory compliance in complex biologics.

  2. Levers To Optimize The IVT Reaction For Increased mRNA Yield 2/10/2026

    Mastering IVT yield requires balancing magnesium and nucleotide ratios. Learn how specific buffers and pyrophosphatase optimize mRNA synthesis for scalable, high-quality therapeutic production.

  3. Your AKTA Oligosynt™ System : It's More Than A Machine 2/9/2026

    Discover how early choices in oligo synthesis workflows shape performance. Learn what to consider across design, reagents, and system optimization to build a process ready for smooth scale‑up.

  4. Selecting A Prefillable Syringe System With Confidence 2/5/2026

    Discover an advancement in the prefillable syringe market, uniquely integrating the syringe barrel, plunger, and needle shield/tip cap into a fully harmonized, verified system from a single supplier.

  5. Protecting Product Integrity Through Cold Chain 2/5/2026

    Reliable temperature‑controlled storage, monitoring, and safeguards keep sensitive materials stable from fill to patient, protecting quality, preventing degradation, and ensuring safety throughout the cold chain.

  6. Integrated Upstream And Downstream Strategies For Robust Manufacturing 2/5/2026

    Process robust mAb production requires understanding scale dependent cell environments, leveraging predictive models, and pursuing data driven control to minimize variability and optimize quality.

  7. Bispecific Antibodies Unleashed 2/4/2026

    Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.

  8. The Benefits Of End-To-End Formulation And Fill/Finish Of Biologics 2/4/2026

    Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.

  9. Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs 2/4/2026

    Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

  10. Designing Drug Substance Processes For Fill-Finish Compatibility 2/4/2026

    Integrated KBI and Argonaut solutions streamline drug substance to fill-finish transitions, resolving quality challenges, reducing delays, and accelerating timelines through coordinated processes and practical strategies.